GGrantIndex
Sort

172,184 grants matching inflammation

Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease

$972,355
William Charles Kreisl · Columbia University Health Sciences · R01 · FY2020 · AG

ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial

$972,337
Janet T. Holbrook · Johns Hopkins University · UG1 · FY2022 · EY

GWAS of Hormone Treatment and CVD and Metabolic Outcomes in the WHI

$972,278
Alexander P Reiner · Fred Hutchinson Cancer Research Center · U01 · FY2011 · HG

Breast White Adipose Tissue Inflammation and Breast Cancer Outcomes

$972,130
Lawrence H Kushi · Kaiser Foundation Research Institute · R01 · FY2021 · CA

Anti-carcinogenic Activity Of Cox inhibitors and NAG-1

$972,039
Thomas Eling · National Institute Of Environmental Health Sciences · ZIA · FY2013 · ES

Gastroesophageal junction stem cells as the origin of Barretts esophagus and cancer

$972,000
Timothy Cragin Wang · Columbia University Health Sciences · R01 · FY2022 · CA

Mechanisms addressing the causal relationships of sleep, circadian rhythms, and cardiometabolic health

$972,000
Marie-Pierre St-Onge · Columbia University Health Sciences · R35 · FY2025 · HL

Glycans in Blood Homeostasis and Disease

$972,000
Karin Maria Hoffmeister · Versiti Wisconsin, Inc. · K12 · FY2019 · HL

Glycans in Blood Homeostasis and Disease

$972,000
Karin Maria Hoffmeister · Versiti Wisconsin, Inc. · K12 · FY2021 · HL

Glycans in Blood Homeostasis and Disease

$972,000
Karin Maria Hoffmeister · Versiti Wisconsin, Inc. · K12 · FY2022 · HL

Glycans in Blood Homeostasis and Disease

$972,000
Karin Maria Hoffmeister · Versiti Wisconsin, Inc. · K12 · FY2020 · HL

Asthma and Allergic Disease Center

$971,931
Thomas A. Platts-Mills · University Of Virginia · U19 · FY2008 · AI

A Systems-level Approach to Studying HIV/AIDS Susceptibility and Substance Abuse

$971,870
Steven M Wolinsky · Northwestern University At Chicago · R01 · FY2012 · DA

Neuroprotective role of GLP-1 receptor agonists

$971,839
Nigel H. Greig · National Institute On Aging · ZIA · FY2021 · AG

Candidate selection of a LPAR1 antagonist for therapeutic application in NASH

$971,732
Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2023 · DK

Studies of neurocysticercosis and animal cestode infections

$971,721
Theodore Nash · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Immune checkpoint inhibitors and accelerated coronary atherosclerosis

$971,495
Tomas G Neilan · Massachusetts General Hospital · R01 · FY2024 · HL

A Mechanistic and Translational Research Program Linking Impaired Resolution, Defective Efferocytosis, and Clonal Hematopoiesis to the Formation of Clinically Dangerous Atherosclerotic Plaques

$971,355
Ira A Tabas · Columbia University Health Sciences · R35 · FY2021 · HL

A Mechanistic and Translational Research Program Linking Impaired Resolution, Defective Efferocytosis, and Clonal Hematopoiesis to the Formation of Clinically Dangerous Atherosclerotic Plaques

$971,347
Ira A Tabas · Columbia University Health Sciences · R35 · FY2022 · HL

A Mechanistic and Translational Research Program Linking Impaired Resolution, Defective Efferocytosis, and Clonal Hematopoiesis to the Formation of Clinically Dangerous Atherosclerotic Plaques

$971,337
Ira A Tabas · Columbia University Health Sciences · R35 · FY2023 · HL

A Mechanistic and Translational Research Program Linking Impaired Resolution, Defective Efferocytosis, and Clonal Hematopoiesis to the Formation of Clinically Dangerous Atherosclerotic Plaques

$971,319
Ira A Tabas · Columbia University Health Sciences · R35 · FY2025 · HL

Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis

$971,267
Yow-Pin Lim · Prothera Biologics, Llc · R44 · FY2025 · AI

Antimicrobial and Regenerative Treatment for Oral Mucositis

$970,980
Shenda Baker · Synedgen, Inc. · R44 · FY2012 · DE

International Studies of the Acquired Immune Deficiency Syndrome (AIDS)

$970,881
Andrew Redd · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Plasma Gelsolin as Immunotherapeutic for Antibiotic-Resistant Pneumonia

$970,844
Lester Kobzik · Harvard School Of Public Health · R01 · FY2017 · AI